Brucellae species are important bacterial zoonotic pathogens which cause brucellosis, an infection with a worldwide distribution. Prevention and diagnosis of infected cases are challenging researches. Surface proteins are valuable antigens as they are most exposed to the host immune system. Many of outer membrane proteins are expected to be capable of eliciting immune response, we are interested on Brucella abortus, outer membrane protein 19 (Omp19). The aim of present study is, producing recombinant Omp19 as a new particle to prevent brucellosis. Using Gene Runner software to design primers. Omp19 amplified by PCR method. pJET1.2 and pET28a (+) were used as cloning and expression vectors respectively. Escherichia coli DH₅a had the role of unexpression host with usual aim of cloning. BamHI and HindIII were applied as restriction enzymes and E. coli BL21 (DE3) as expression host. Recombinant Omp19 devoid of other Brucella antigens will allow determination of the potential protective activity against brucellosis.

Vaccination against animal brucellosis is usually performed by using living attenuated Brucella strains. These vaccines have numerous disadvantages due to basic infections with both animals and mankind. They also elicit antibodies against the Lipopolysaccharide (LPS) which interfere in the differential diagnosis between vaccinated and infected animals. So, accessing to the method or technique to improve new vaccines is an aim in brucellosis investigation. Production of recombinant 18kDa outer membrane lipoprotein of Brucella abortus (Omp19) gave a new vision for preventional researches. Sequencing results of the cloned plasmid vector confirmed the cloning procedure. Gene fragment was subsequently subcloned in expression system pET28a(+). Expression of recombinant protein was induced by adding 1mM IPTG to the growing culture of OD 0.6. Cloning and expression of recombinant 18kDa outer membrane lipoprotein of Brucella abortus (Omp19) allow the evaluation of the potential protective activity and the possibility for the development of subunit vaccines in further investigations.